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Clinical implications of the plasma 
EphA2 receptor level in critically ill 
patients with septic shock
Su Hwan Lee1,3, Ju Hye Shin2,3, Joo Han Song2,3, Ah Young Leem2,3, Moo Suk Park2,3, Young 
Sam Kim2,3, Joon Chang2,3 & Kyung Soo Chung  2,3
The Eph/ephrin receptor ligand system is known to play a role in inflammation induced by infection, 
injury, and inflammatory diseases. The present study aimed to evaluate plasma EphA2 receptor levels 
in critically ill patients with sepsis. This study was a prospective cohort study evaluating samples and 
clinical data from the medical intensive care unit (MICU) of a 2000-bed university tertiary referral 
hospital in South Korea. Positive correlations of the plasma EphA2 receptor level with the acute 
physiology and chronic health evaluation (APACHE) II score and the sequential organ failure assessment 
(SOFA) score were observed. The area under the curve (AUC) for the plasma EphA2 receptor level on a 
receiver operating characteristic curve was 0.690 (95% confidence interval [CI], 0.608–0.764); the AUCs 
for the APACHE II score and SOFA scores were 0.659 (95% CI, 0.576–0.736) and 0.745 (95% CI, 0.666–
0.814), respectively. A Cox proportional hazard model identified an association between an increased 
plasma EphA2 receptor level (>51.5 pg mL−1) and increased risk of 28-day mortality in the MICU (hazard 
ratio = 3.22, 95% CI, 1.709–6.049). An increased plasma EphA2 receptor level was associated with sepsis 
severity and 28-day mortality among sepsis patients.
The progression of infection-induced sepsis leads to organ dysfunction and is associated with a high rate of 
mortality1. Although the sepsis mortality rate has significantly decreased over the years, this condition remains 
difficult to treat2. Furthermore, the reported incidence of sepsis has increased because of several factors, including 
an increase in elderly populations with more comorbidities3–6. In addition, half of all sepsis patients are managed 
in intensive care units (ICUs), and more than 25% of cases end in death7,8.
Vascular endothelial dysfunction plays a key role in the organ failure and mortality associated with sepsis2. 
Sepsis alters the endothelial barrier function, thus enhancing the passage of water, soluble proteins, and cellular 
components from the blood to the tissues9. In addition to conventional treatments such as early antibiotics and 
conservative management, the use of several anti-inflammatory or immunomodulatory therapies has been stud-
ied to combat the pro-inflammatory stage of sepsis10. However, several attempts to target tumor necrosis factor 
(TNF)-α, interleukin (IL)-1 β, toll-like receptors, and endotoxin have not been effective in clinical trials10–12.
Eph receptors comprise the largest family of tyrosine kinase receptors and, with ephrin ligands, are involved 
in cell-to-cell communication. Interactions between Eph receptors and ephrin ligands affect the pathogeneses 
of many conditions including wound healing, ischemia reperfusion injury, nerve injury, endothelial injury, and 
epithelial injury13–16. Eph receptors and ephrin ligands also regulate important processes during embryonic neu-
ronal development, angiogenesis, and oncogenesis13,16. Recently, many studies have focused on the complex roles 
of Eph and ephrin in malignancy17,18. According to several studies, the EphA2 receptor and ephrinA1 ligand also 
affect inflammation via vascular endothelial injury. In an in vivo study in rats, ephrin A1 induced histological 
endothelial disruption in the lung and blocking EphA2 signaling markedly reduced leakage of albumin13,16,19. 
Another study showed that EphA2 activation induced expression of vascular cell adhesion molecule-1 and 
E-selectin20. The EphA2 receptor may be associated with sepsis due to the important role of endothelial injury 
in sepsis21,22. However, clinical studies investigating the association between the EphA2 receptor and sepsis are 
currently lacking.
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We have found that the plasma EphA2 receptor level is elevated in sepsis patients, and therefore, we investi-
gated the clinical implications of the plasma EphA2 receptor level with regard to sepsis. The primary outcome 
of the study was the association between the plasma EphA2 receptor level and all-cause 28-day mortality among 
sepsis patients. The secondary outcomes were an evaluation of the correlations between plasma EphA2 receptor 
levels and severity of sepsis as determined by the acute physiology and chronic health evaluation (APACE) II 
score and the sequential organ failure assessment (SOFA) score23,24. Because EphA2 receptor blocking antibodies 
are already undergoing clinical trials for cancer25–28, we also investigated the plasma EphA2 receptor level as a 
potential marker for therapeutic monitoring in sepsis patients.
Results
Demographic characteristics of the overall study population. A total of 262 patients were admitted 
to our medical ICU (MICU) between March 2015 and August 2015. Of these, 145 patients presented with sys-
temic inflammatory response syndrome (SIRS), sepsis, severe sepsis, or septic shock and agreed to participate in 
this study (Fig. 1). The baseline characteristics of the study population are represented in Table 1. The patient pop-
ulation mostly consisted of older individuals (median age, 70 years) with a higher proportion of men than women 
(65.5% vs. 35.5%). Patients with severe sepsis and septic shock accounted for 73.1% of the study population. The 
median score on the Charlson Comorbidity Index was 3 (interquartile range [IQR], 2–5), and only 6 patients did 
not present with comorbidities. The incidence of acute respiratory distress syndrome (ARDS) and positive blood 
culture were 18.6% and 25.5%, respectively. The most common site of infection was the lung (59.3%), followed 
by the gastrointestinal tract (10.3%). The median acute physiology and chronic health evaluation (APACHE) II 
score was 25 (IQR, 18–31), and the median sequential organ failure assessment (SOFA) score was 10 (IQR, 7–13). 
Overall, 43 patients (29.7%) died within 28 days of admission to the MICU.
Comparison of characteristics between 28-day survivors and 28-day non-survivors. This 
study divided patients into two groups according to 28-day mortality: patients in the case group died within 28 
days of admission to the MICU, whereas those in the control group survived longer than 28 days. The results 
of this inter-group comparison are shown in Table 2. The groups did not differ significantly with regard to sex, 




Age (years) 70 (61–77)
Sex (male) 95 (65.5)
APACHE II score 25 (18–31)
SOFA score 10 (7–13)
ARDS 27 (18.6)
Severe sepsis and septic shock 106 (73.1)
Positive of blood culture 37 (25.5)
Charlson Comorbidity Index 3 (2–5)
CHF 24 (16.6)
DM 45 (31.0)
CKD or ESRD 33 (22.8)
CRP (mg L−1) 87.3 (22.3–141.2)
Procalcitonin (ng mL−1) 0.8 (0.2–6.2)
Table 1. The characteristics of the patients. Values are expressed as n (%) or median (interquartile range) unless 
otherwise indicated; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure 
assessment; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; DM, diabetes mellitus; 
CKD, chronic kidney disease; ESRD, end stage renal disease; CRP, C-reactive protein.
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median age, and median body mass index (BMI). Regarding clinical parameters, the groups did not differ in 
terms of the rate of positive blood cultures and median scores on the Charlson Comorbidity Index. However, the 
non-survivor group had higher rates of ARDS (32.6% vs. 12.7% for survivors, P = 0.005) and a sepsis status above 
severe (86.0% vs. 67.6% for survivors, P = 0.022). The median APACHE II score (29 vs. 24, P = 0.002) and median 
SOFA score (13 vs. 8, P < 0.001) were also significantly higher in the non-survivor group relative to the survi-
vor group. Regarding laboratory parameters, no differences were observed between survivors and non-survivors 
in the median levels for C-reactive protein (CRP) (73.5 mg mL−1 vs. 97 mg mL−1, P = 0.347) and procalcitonin 
(0.5 ng mL−1 vs. 1.8 ng mL−1, P = 0.181) on the day of admission. However, the median plasma EphA2 receptor 
level was significantly higher in the non-survivor group than in the survivor group (78.5 pg mL−1 vs. 33.3 pg mL−1, 
P < 0.001).
Association between the plasma EphA2 receptor level and severity or mortality. Positive cor-
relations were observed between the plasma EphA2 receptor level and the APACHE II (r = 0.291, P < 0.001) 
and SOFA (r = 0.341, P < 0.001 Fig. 2) scores. Stratification of patients according to the IQRs for SOFA scores 
revealed an increasing trend in SOFA scores with increasing plasma EphA2 receptor levels (SOFA score <6 vs. 
SOFA score >13, P < 0.001; Fig. 3). The Area under the curve (AUC) for the plasma EphA2 receptor level on a 
receiver operating characteristic (ROC) curve was 0.690 (95% confidence interval [CI], 0.608–0.764); the AUCs 
for the APACHE II score and SOFA score were 0.659 (95% CI, 0.576–0.736) and 0.745 (95% CI, 0.666–0.814), 
respectively. In ROC curve comparisons, the AUC of the plasma EphA2 receptor level and SOFA score (0.690 vs. 
0.745, P = 0.256) and APACHE II score (0.690 vs. 0.659, P = 0.605) did not differ significantly. However, the AUC 
of the SOFA score and APACHE II score differed significantly (0.745 vs. 0.659, P = 0.034; Fig. 4a).
A cut-off value of >51.5 pg mL−1 for the plasma EphA2 receptor level was determined to predict 28-day mor-
tality on the ROC (sensitivity, 62.8%; specificity, 71.6%). Patients were divided into two groups according to 
this plasma EphA2 receptor cut-off level of 51.5 pg mL−1 and subjected to a Cox proportional hazard model 
analysis involving several demographic and clinical characteristics and substituted plasma EphA2 receptor levels 
(Table 3). In the univariate analysis, an increased plasma EphA2 receptor level (>51.5 pg mL−1; hazard ratio, 
3.41; 95% CI, 1.750–6.636) was associated with 28-day mortality. In the multivariate analysis, sex, age, BMI, 
positive blood culture and sepsis status higher than severe were not found to be associated with 28-day mortal-
ity; in contrast, ARDS (hazard ratio, 2.02; 95% CI, 1.051–3.389) and an increased plasma EphA2 receptor level 
(>51.5 pg mL−1; hazard ratio, 3.22; 95% CI, 1.709–6.049) were associated with increased 28-day mortality in the 
MICU. Figure 4b shows the survival rates of the groups classified according to plasma EphA2 receptor levels; 
these survival rates differed significantly (P < 0.001).
Variables
Survivor Non-survivor
p(n = 102) (n = 43)
Sex (male) 67 (65.7) 28 (65.1) 0.947
Age (year) 69 (57.8–77.0) 72 (63.1–84.2) 0.202
Body mass index (kg m−2) 20.6 (18.9–26.6) 21.7 (19.4–30.0) 0.081
Clinical parameters
  ARDS 13 (12.7) 14 (32.6) 0.005
  Severe sepsis or septic shock 69 (67.6) 37 (86.0) 0.022
  Positive blood culture 24 (23.5) 13 (30.2) 0.398
  Charlson Comorbidity Index 3 (1.0–4.3) 3 (2.0–5.0) 0.080
  APACHE II score 24.0 (16.8–29.2) 29.0 (20.0–36.0) 0.002
  SOFA score 8.0 (6.0–11.3) 13.0 (10.0–16.0) <0.001
Laboratory parameters
  CRP (mg mL−1) 73.5 (17.5–158.4) 97.0 (47.0–186.0) 0.347
  Procalcitonin (ng mL−1) 0.5 (0.1–6.3) 1.8 (0.5–5.7) 0.181
  DNI (%) 3.2 (1.1–6.9) 3.8 (2.1–13.3) 0.202
  RDW (%) 15.0 (14.1–16.5) 17.1 (15.9–19.6) <0.001
  EphA2 (pg mL−1) 33.3 (18.8–71.0) 78.5 (36.3–164.5) <0.001
  IL-1β (pg mL−1) 14.5 (12.0–26.8) 19.0 (12.0–31.3) 0.327
  IL-10 (pg mL−1) 84.8 (27.5–127.9) 99.5 (28.5–465.5) 0.113
  IL-18 (pg mL−1) 408.6 (267.9–751.3) 835.5 (467.8–1719.0) <0.001
  IL-6 (pg mL−1) 311.6 (109.3–1123.6) 2329.2 (247.5–7570.0) 0.002
  TNF-α (pg mL−1) 41.0 (27.7–70.2) 45.0 (27.3–100.3) 0.320
  IP-10 (pg mL−1) 618.6 (217.2–2205.9) 1597.0 (499.3–5468.3) 0.013
Table 2. Comparison of Characteristics Between 28-day Survivors and 28-day Non-survivors (n = 145). Values 
are expressed as n (%) or median (interquartile range) unless otherwise indicated; ARDS, acute respiratory 
distress syndrome; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure 
assessment; DNI, delta neutrophil index; RDW, red cell distribution width; IL, interleukin; TNF, tumor necrosis 
factor; IP, induced protein.
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Discussion
In the current study, we investigated potential associations of the plasma EphA2 receptor level with sepsis sever-
ity and 28 day-mortality among sepsis patients in the MICU. The main finding of this study was that the plasma 
EphA2 receptor level correlates with sepsis severity scores and increased mortality among sepsis patients.
The APACHE II score and SOFA score are commonly used for initial severity assessments in sepsis 
patients23,29. The plasma EphA2 receptor level was comparable to these scores. The results of this analysis consist-
ently indicated that an increased plasma EphA2 receptor level was related to the initial severity of sepsis. A higher 
SOFA score is associated with increased patient mortality24. In this study, plasma EphA2 receptor levels were eval-
uated in groups according to interquartile ranges of SOFA scores (Fig. 3). The result showed that a higher plasma 
EphA2 receptor level was associated with mortality in sepsis patients. The AUC of the ROC curve and results of 
the Cox hazard proportional model supported this association. Furthermore, we used a plasma EphA2 receptor 
cut-off value to discriminate mortality risk according to the Cox hazard proportional model. As a result, a plasma 
EphA2 receptor level >51.5 pg mL−1 was associated with a significant increase in mortality (hazard ratio, 3.22).
As mentioned previously, many studies have focused on the complex roles of the Eph receptor and ephrin 
ligand in malignancy30,31. Several studies have reported associations of EphA2 with multiple oncogenic signaling 
pathways such as MAP/ERK, phosphoinositide 3-kinase, E-cadherin, and integrin/FAK/paxillin30,32–34. In the 
field of oncology, the EphA2 receptor has been studied as a therapeutic target and is being investigated in an 
ongoing clinical trial in patients with advanced malignancies25–28. Tumor development, progression, and thera-
peutic responses may be affected by inflammation17. Cancer and infectious disease have many similarities. For 
example, inhibitors of programmed cell death ligand 1, which were developed for patients with cancer, have also 
been actively investigated as therapeutic agents for chronic infection and/or sepsis18. Accordingly, it is notewor-
thy that the Eph2 receptor and ephrin ligand also affect inflammation through vascular endothelial injury13,16,19. 
Figure 2. Positive correlations were observed between the plasma EphA2 receptor level and the (a) APACHE II 
and (b) SOFA scores.
Figure 3. Stratification of patients according to the interquartile ranges of SOFA scores revealed an increasing 
trend in SOFA scores with increasing plasma EphA2 receptor levels.
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EphA2 and other inflammatory mediators, such as TNF-α and interferon (IFN)-γ, upregulate NF-κB, thus 
increasing intercellular adhesion molecule-1 expression and facilitating leukocyte migration and attachment19,35. 
Several emerging studies have shown a link between the EphA2 receptor and inflammation36–40. Animal models 
of lipopolysaccharide (LPS)-induced pneumonia have demonstrated an increase in the EphA2 receptor level after 
LPS exposure37. Another study reported the increased expression of EphA2 receptor with lung injury and found 
that EphA2 receptor blockade reduced lung injury and the passage of fluids and inflammatory cells41. EphA2 
receptor signaling is associated with Src family kinases, mitogen activated protein kinase, p-21 activated kinase, 
post-synaptic density protein 95-dependent pathways, chemokine pathways, heterotrimeric G-protein pathways, 
and integrin-mediated pathways19,22. A recent study reported that the p-21 activated kinase was strongly asso-
ciated with endothelial barrier in a sepsis murine model22. Given the results of this study and others, EphA2 
receptor blockade may be a reasonable treatment target for reducing endothelial injury in sepsis patients. Unlike 
malignancy, however, sepsis does not involve a target lesion. Therefore, an appropriate blood marker with which 
to assess the therapeutic drug effect is needed if EphA2 receptor blocking is to be used as a therapeutic target. The 
plasma EphA2 receptor level may be useful to evaluate the effect of treatment in this setting.
The strengths of this study include the confirmed measurement of blood plasma EphA2 receptor levels and the 
identification of an association between human plasma EphA2 receptor levels and sepsis. These results provide 
clinical evidence for the use of EphA2 receptor as a therapeutic target in sepsis and provide a potential tool for 
monitoring responses to EphA2 receptor blocker treatment in sepsis patients.
However, our study has several limitations. First, this was a small study of plasma EphA2 receptor levels in 
sepsis patients at a single center without pediatric patients. However, this study is the first clinical study to use 
human blood samples to evaluate the relationship between plasma EphA2 receptor levels and sepsis. Previously, 
other studies investigated the relationship between the EphA2 receptor and inflammation. Most of these studies 
used in vitro or animal models36,37,39,42. However, no clinical proof of sepsis was provided. Second, the plasma 
EphA2 receptor level measurements have not been validated. The importance of proteases in regulating the Eph 
receptor and the ephrin ligand family has been shown43; it is thought that the proteases that activate the Eph 
Figure 4. (a) In ROC curve comparisons, the AUC of the plasma EphA2 receptor level and SOFA scores 
(0.690 vs. 0.745, P = 0.256) and APACHE II scores (0.690 vs. 0.659, P = 0.605) did not differ significantly. (b) 
Kaplan-Meier survival analysis showed that the 28-day mortality of patients with plasma EphA2 receptor level 
≥51.5 pg mL−1 was higher than that of patients with plasma EphA2 receptor level <51.5 pg mL−1.
Variable
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Sex (male) 1.22 0.641–2.316 0.546
Age (year) 1.02 0.998–1.044 0.076 1.02 0.999–1.045 0.056
BMI (kg m−2) 1.04 0.960–1.131 0.320
ARDS 1.96 0.996–3.838 0.051 2.02 1.051–3.887 0.035
Positive Blood culture 0.68 0.334–1.375 0.281
EphA2 (≥51.5 pg mL−1) 3.41 1.750–6.636 <0.001 3.22 1.709–6.049 <0.001
Severe sepsis and septic shock 2.48 0.992–6.205 0.052 2.32 0.970–5.541 0.059
Table 3. Cox proportional hazard model of plasma EphA2 level and 28-day mortality. HR, hazard ratio; CI, 
confidence interval; BMI, body mass index; ARDS, acute respiratory distress syndrome.
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receptor and the ephrin ligand family also degrade the Eph A2 receptor into the cleaved form, which in turn 
increases EphA2 receptors in the plasma. However, it is unclear whether the measured EphA2 receptor reflects 
the soluble or membrane-bound form due to limitation of the kit used in this study. Furthermore, in vitro and 
in vivo evidence that clearly supports an association between plasma EphA2 receptor signaling and sepsis is rare. 
Third, we did not analyze serial EphA2 receptor levels because we were unable to collect serial blood samples 
from the patients. Therefore, additional studies investigating the measurement of plasma EphA2 receptor levels in 
sepsis patients and evidence of an association between EphA2 receptor signaling and sepsis are needed.
Conclusion
An increased plasma EphA2 receptor level was associated with sepsis severity and 28-day mortality among sepsis 
patients. The plasma EphA2 receptor may be considered a potential therapeutic target in sepsis patients. The EphA2 
receptor level may be used for treatment monitoring in sepsis patients treated with an EphA2 receptor blocker.
Methods
Study design, patients, and clinical setting. This was a prospective cohort study of patients and col-
lected samples from the MICU of Severance Hospital, a 2000-bed (30-bed MICU) university tertiary referral 
hospital in Seoul, South Korea. The study considered 262 consecutive patients aged >19 years who were admitted 
to the MICU between March 2015 and August 2015. The study ultimately enrolled a total of 145 patients who 
presented with SIRS, sepsis, severe sepsis, or septic shock as defined by the American College of Chest Physicians/
Society of Critical Care Medicine Consensus Conference5,44. All patients presenting with SIRS, sepsis, severe sep-
sis, or septic shock were treated according to the guidelines of the Surviving Sepsis Campaign5.
Clinical data and blood sample collection. Data of all patients admitted to the MICU were collected 
from the hospital electronic medical records and their blood samples. The severity of each patient’s condition 
was classified according to two different scoring systems: The SOFA and APACHE II scores were calculated23,29. 
In addition, the Charlson Comorbidity Index was used to evaluate patients’ comorbidities45. Clinical parameters 
such as the development of ARDS, blood culture positivity, 28-day mortality, and other demographic character-
istics were evaluated.
Venous blood samples were collected within 24 hours after admission to the MICU though central lines into 
tubes containing ethylenediaminetetraacetic acid. Simultaneously, we determined the CRP, procalcitonin, cre-
atinine, and albumin levels, blood culture results, white blood cell and platelet counts, and APACHE II and 
SOFA scores. Plasma was prepared by centrifugation for 15 minutes at 800 × g and 4 °C. Supernatants from cen-
trifuged blood were immediately aliquoted and stored at −80 °C until the analysis was performed. Plasma levels 
of the EphA2 receptor and other cytokines (IL-1β, IL-10, IL-18, IL-6, TNF-α, and interferon gamma induced 
protein-10) were measured using the Human Magnetic Luminex® Screening Assay Kit (R&D Systems, Inc., 
Minneapolis, MN, USA). The kit detects all forms of the EphA2 receptor including the soluble, membrane-bound, 
phosphorylated and non-phosphorylated forms All samples and standards were assayed in duplicate using the 
Luminex 200TM System (Merck Millipore, Darmstadt, Germany).
Ethical approval. The study protocol was submitted as an ICU cohort and approved by the Institutional 
Review Board (IRB) of Severance Hospital (IRB number: 4-2013-0585). All study procedures were performed 
in accordance with the relevant guidelines and regulations. In addition, this study was performed in compliance 
with the principles set forth in the Declaration of Helsinki.
Statistical analysis. Data are described as medians with IQRs. The chi-squared and Fisher’s exact tests or 
the Mann–Whitney U test was used to assess differences between the two groups. The Kruskal–Wallis test was 
used to compare three or more groups of a qualitative parameter. Pearson correlation analyses were performed to 
estimate associations between the biomarkers and the APACHE II and SOFA scores. AUC analyses of ROC curves 
were performed to compare the plasma EphA2 receptor level, APACHE II score, and SOFA score. Subsequently, 
the 28-day survivor and non-survivor groups were analyzed using a Cox proportional hazard model with a 
plasma EphA2 receptor level cut-off value to predict 28-day mortality according to the ROC and several varia-
bles. The Kaplan–Meier method was used to report survival curves that were analyzed using the log-rank test. In 
all cases, a p-value of <0.05 was considered statistically significant. SPSS version 20 (IBM, Armonk, NY, USA) 
was used for statistical analyses; AUC analyses of ROC curves were performed using MedCalc software (version 
16.4.3; MedCalc, Oostende, Belgium).
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